Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety and Pharmacokinetics of Dolutegravir 50 mg Once Daily With Food Versus Dolutegravir 50 mg Twice Daily in HIV/TB Co-infected Patients Receiving Rifampin-based Antituberculosis Therapy

NCT03731559 is registered in ClinicalTrials.gov with The HIV Netherlands Australia Thailand Research Collaboration as lead sponsor.

NCT NCT03731559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03731559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety and Pharmacokinetics of Dolutegravir 50 mg Once Daily With Food Versus Dolutegravir 50 mg Twice Daily in HIV/TB Co-infected Patients Receiving Rifampin-based Antituberculosis Therapy
Lead sponsor
The HIV Netherlands Australia Thailand Research Collaboration
Phase
Phase 2
Overall status
Completed
Start date
June 25, 2019
Completion date
June 30, 2025
Enrollment
123 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hiv/tb coinfection